Chevy Chase Trust Holdings LLC Sells 2,172 Shares of IQVIA Holdings Inc. $IQV

Chevy Chase Trust Holdings LLC reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.4% during the second quarter, Holdings Channel.com reports. The fund owned 90,157 shares of the medical research company’s stock after selling 2,172 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in IQVIA were worth $14,208,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Stratos Wealth Partners LTD. increased its position in shares of IQVIA by 10.5% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 7,149 shares of the medical research company’s stock valued at $1,127,000 after purchasing an additional 681 shares during the last quarter. Private Trust Co. NA increased its position in shares of IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 67 shares during the last quarter. Nordea Investment Management AB increased its position in shares of IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares during the last quarter. Callahan Advisors LLC increased its position in shares of IQVIA by 17.2% during the 2nd quarter. Callahan Advisors LLC now owns 43,475 shares of the medical research company’s stock valued at $6,851,000 after purchasing an additional 6,368 shares during the last quarter. Finally, Generali Asset Management SPA SGR increased its position in shares of IQVIA by 30.0% during the 2nd quarter. Generali Asset Management SPA SGR now owns 37,624 shares of the medical research company’s stock valued at $5,929,000 after purchasing an additional 8,689 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQV opened at $204.51 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $237.21. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s 50 day simple moving average is $191.41 and its 200 day simple moving average is $169.19. The firm has a market cap of $34.77 billion, a price-to-earnings ratio of 29.60, a PEG ratio of 2.25 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter last year, the business posted $2.64 EPS. The business’s revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on IQV shares. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Cowen reiterated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $234.57.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.